Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDR-001 in Healthy and Obese/Overweight Participants
NCT06778850Phase 2Completed
- Sponsor
- MindRank
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MDR-001 in obesity (4 arms), sponsored by MindRank. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Day 84. Started Jun 2023; status: completed.
02
Drugs
MDR-001
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06778850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778850.